US OptionsDetailed Quotes
SLS241115C5000
- 0.05
- 0.000.00%
15min DelayClose Nov 4 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume4.75K Open Interest5.00Strike Price0.00Turnover530.33%IV331.62%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1311Delta0.1980Gamma23.40Leverage Ratio-0.0101Theta0.0000Rho3.07Eff Leverage0.0004Vega
Sellas Life Sciences Stock Discussion
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...
Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas
No comment yet